Early signs from the launch of Novo Nordisk’s Wegovy pill and Eli Lilly & Co.’s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Source: US Top News and Analysis
Related Posts
Milken-adjacent Power100 attendees aim to reclaim the DEI in finance narrative
Blueprint Capital’s Power100 weekend convenes diverse leaders in finance ahead of the Milken Institute Global…
Hegseth, Caine testifying on Pentagon budget amid Iran war
Lawmakers are grilling Hegseth and Caine about the Pentagon budget for next year, but the…
Trump says ‘Iran wants to make a deal, but I’m not satisfied with it’
Trump said “is tremendous discord” among Iran’s leaders, which has complicated efforts to end the…